Leading healthcare company, MSD, has announced it is to invest €40 million this year in its manufacturing facility in Ballydine, Co. Tipperary, as part of a total spend of €75 million over the last three years to enhance the site’s facilities. Pictured at the announcement are: Ger Carmody, Site Lead, MSD in Ballydine, and Ger Brennan, Managing Director for Human Health at MSD Ireland.
Leading healthcare company, MSD, has announced it is to invest €40 million this year in its manufacturing facility in Ballydine, Co. Tipperary, as part of a total spend of €75 million over the last three years to enhance the site’s facilities. The spend in 2017 includes the installation of a new spray drying facility at the plant - a technology used in a number of new products to increase their solubility and improve how the medicines are absorbed by patients.
MSD Ballydine develops and supplies the active ingredients and final formulated product for a range of innovative medicines at its manufacturing and R&D facilities. The plant, which last year marked 40 years in operation, exports to over 30 countries around the world with primary markets being Europe, USA and Japan.
According to Ger Carmody, Site Lead at MSD in Ballydine, “This investment reflects the growing importance of MSD Ireland’s operations to our global network, and is a fitting way to mark 40 years of MSD in Ballydine. As a leading healthcare company, our growth and development has been built on continually embracing new ways of working, as well as the latest cutting edge technologies. Our highly-skilled local workforce is now leading the way in the development of new medicines, including MSD’s new treatment for hepatitis C, which is being manufactured in Tipperary for patients around the world.”
Chamber News & Events
Read some of our past events and posts,